Abstract: The invention discloses multiple genes related to age-related macular degeneration (AMD) and/or phagocytosis by RPE cells of the eye, and methods and compositions for detecting and treating AMD and other retinal degenerative conditions based on these phagocytosis-related and/or AMD-related genes. Also provided are animal models useful for testing therapeutic compounds and treatment protocols for AMD, and gene arrays including polymorphic variants of phagocytosis-related and/or AMD-related genes, useful for genetic screening of nucleic acid samples from subjects to obtain profiles of polymorphic variant sequences in a plurality of genes associated with AMD.
Abstract: Disclosed are novel methods of treatment for retinal diseases and conditions including age-related macular degeneration, genetic-based retinal degenerations and retinal detachment. A novel glycan binding protein thought to be a cell surface receptor has been discovered in the retina. The retinal glycan binding receptor is shown to play an important role in promoting assembly of outer segment (OS) membranes by the photoreceptor cells of the eye, a process that is essential for vision. Based on the finding that certain sugars can bind with very high affinity to the retinal glycan receptor and stimulate its function, the invention provides novel therapeutic agents for treatment of retinal diseases that are multivalent N-linked glycans. Preferred pharmaceutical compositions in accordance with the present invention comprise active agents having the general formula: (Gal-GlcNAc)n-Man3-GlcNAc2, where n is 1-4.
Type:
Grant
Filed:
March 28, 2008
Date of Patent:
January 10, 2012
Assignee:
The University of Tennessee Research Foundation
Abstract: The invention comprises a composition of matter and method of its use for the treatment of multiple sclerosis in humans. The composition is a modified anticholinergic alpha-neurotoxin. Alpha-neurotoxin solution, such as cobratoxin, is filter sterilized to remove bacteria. It is modified using H2O2. Any suitable preservative for parenteral administration can be employed such as methyl paraben, benzalkonium chloride or metacreosol. It is preferred that the composition is administered every other day or daily. The composition may be administered orally, subcutaneously, intramuscularly or intravenously. Parenterally, either subcutaneous or intramuscular injection is preferred.
Abstract: A composition for cellulostic fibers containing amino silicone to impart improved hand feel. The composition may be included in a lotion applied to tissue paper and may include a hydrophilic softener. A carrier for trace substances, fragrances, vitamin E, aloes and colouring agents may also be used. Such carrier may comprise microcapsules.
Type:
Grant
Filed:
October 6, 2009
Date of Patent:
August 23, 2011
Assignee:
Kruger Products L.P.
Inventors:
Philip Buder, Vincent Denis Landry, Charles William Alexander Stewart, Jose Enrique Castell Perez, Richard Hector Gendron, Marc Joseph Gilles Desaulniers
Abstract: A composition of matter for an analgesia and its method of use is disclosed. The method of use is for the treatment of chronic pain, especially to the treatment of heretofore intractable pain as associated with advanced cancer. The pain associated with neurological conditions, rheumatoid arthritis, viral infections and lesions is also contemplated. The method includes administering to a host an alpha-neurotoxin that is characterized by its ability to blocking of the action of acetylcholine at nicotinic acetylcholine receptors.
Abstract: Detoxified cobra venom and its constituent neurotoxins have been reported to have potent antiviral activity. Others have reported that snake venoms were generally immune stimulants. Recent research has revealed more specific details on the effects of detoxified venoms and isolated alpha-neurotoxins on cells of the immune system. Exposure of the immune cells to these detoxified proteins yields a strong response in the innate immune reaction that represents the immune systems initial response to infectious agents. Of particular relevance is the marked increase in the expression of genes associated with the production of gamma interferon, a potent antiviral agent and regulator of the immune response. The ability to induce this strong innate response has significant application to those with weakened immune systems where their ability to fight infection has been compromised.
Abstract: A composition for cellulostic fibers containing amino silicone to impart improved hand feel. The composition may be included in a lotion applied to tissue paper and may include a hydrophilic softener. A carrier for trace substances, fragrances, vitamin E, aloes and coloring agents may also be used. Such carrier may comprise microcapsules.
Type:
Grant
Filed:
April 8, 2002
Date of Patent:
October 6, 2009
Inventors:
Philip Buder, Vincent Landry, Charles William Alexander Stewart, Jose Enrique Castell Perez, Richard Hector Gendron, Marc Joseph Gilles Desaulniers